R&D
In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 109 companies plus partners who are today developing 134 IL-5 pathway targeting drugs in 514 developmental projects in cancer across 116 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More -
Biologicals in Oncology Drug Pipeline Update 2013
$3,425.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 860 companies plus partners who are today developing 1460 biological drugs in 3194 developmental projects in cancer across 576 different targets. In addition, there are 25 suspended drugs and another 868 drugs where development has been ceased. Learn More -
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 172 companies plus partners who are today developing 222 IL-3 pathway targeting drugs in 789 developmental projects in cancer across 129 different targets. In addition, there are 4 suspended drugs and another 82 drugs where development has been ceased. Learn More -
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 221 companies plus partners who are today developing 256 nucleic acid therapy drugs in 567 developmental projects in cancer across 187 different targets. In addition, there are 7 suspended drugs and another 180 drugs where development has been ceased. Learn More -
Analytical Tool - Angiogenesis in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More -
Analytical Tool - Breast Cancer
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More -
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 207 companies plus partners who are today developing 276 B cell receptor pathway targeting drugs in 1001 developmental projects in cancer across 155 different targets. In addition, there are 5 suspended drugs and another 103 drugs where development has been ceased. Learn More -
Analytical Tool - Apoptosis in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic mechanism. Learn More -
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 313 companies plus partners who are today developing 395 Androgen Receptor drugs in 1261 developmental projects in cancer across 181 different targets. In addition, there are 4 suspended drugs and another 196 drugs where development has been ceased. Learn More -
Analytical Tool - Melanoma
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013This report offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D. Learn More -
Notch Signaling Pathway in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 159 companies plus partners who are today developing 175 Notch pathway targeting drugs in 583 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 104 drugs where development has been ceased. Learn More -
ID Signaling Pathway in Oncology Drug Pipeline Update 2013
$685.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 33 companies plus partners who are today developing 24 ID pathway targeting drugs in 112 developmental projects in cancer across 34 different targets. In addition, there is 1 suspended drug and another 15 drugs where development has been ceased. Learn More -
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 53 companies plus partners who are today developing 51 IL-9 pathway targeting drugs in 216 developmental projects in cancer across 45 different targets. In addition, there is 1 suspended drug and another 20 drugs where development has been ceased. Learn More -
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 238 companies plus partners who are today developing 296 TNF-alpha pathway targeting drugs in 1016 developmental projects in cancer across 176 different targets. In addition, there are 2 suspended drugs and another 144 drugs where development has been ceased. Learn More -
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 243 companies plus partners who are today developing 321 IL-6 pathway targeting drugs in 1010 developmental projects in cancer across 153 different targets. In addition, there are 2 suspended drugs and another 132 drugs where development has been ceased. Learn More
R&D
In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 109 companies plus partners who are today developing 134 IL-5 pathway targeting drugs in 514 developmental projects in cancer across 116 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More -
Biologicals in Oncology Drug Pipeline Update 2013
$3,425.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 860 companies plus partners who are today developing 1460 biological drugs in 3194 developmental projects in cancer across 576 different targets. In addition, there are 25 suspended drugs and another 868 drugs where development has been ceased. Learn More -
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 172 companies plus partners who are today developing 222 IL-3 pathway targeting drugs in 789 developmental projects in cancer across 129 different targets. In addition, there are 4 suspended drugs and another 82 drugs where development has been ceased. Learn More -
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 221 companies plus partners who are today developing 256 nucleic acid therapy drugs in 567 developmental projects in cancer across 187 different targets. In addition, there are 7 suspended drugs and another 180 drugs where development has been ceased. Learn More -
Analytical Tool - Angiogenesis in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More -
Analytical Tool - Breast Cancer
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More -
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 207 companies plus partners who are today developing 276 B cell receptor pathway targeting drugs in 1001 developmental projects in cancer across 155 different targets. In addition, there are 5 suspended drugs and another 103 drugs where development has been ceased. Learn More -
Analytical Tool - Apoptosis in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic mechanism. Learn More -
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 313 companies plus partners who are today developing 395 Androgen Receptor drugs in 1261 developmental projects in cancer across 181 different targets. In addition, there are 4 suspended drugs and another 196 drugs where development has been ceased. Learn More -
Analytical Tool - Melanoma
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013This report offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D. Learn More -
Notch Signaling Pathway in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 159 companies plus partners who are today developing 175 Notch pathway targeting drugs in 583 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 104 drugs where development has been ceased. Learn More -
ID Signaling Pathway in Oncology Drug Pipeline Update 2013
$685.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 33 companies plus partners who are today developing 24 ID pathway targeting drugs in 112 developmental projects in cancer across 34 different targets. In addition, there is 1 suspended drug and another 15 drugs where development has been ceased. Learn More -
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 53 companies plus partners who are today developing 51 IL-9 pathway targeting drugs in 216 developmental projects in cancer across 45 different targets. In addition, there is 1 suspended drug and another 20 drugs where development has been ceased. Learn More -
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 238 companies plus partners who are today developing 296 TNF-alpha pathway targeting drugs in 1016 developmental projects in cancer across 176 different targets. In addition, there are 2 suspended drugs and another 144 drugs where development has been ceased. Learn More -
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 243 companies plus partners who are today developing 321 IL-6 pathway targeting drugs in 1010 developmental projects in cancer across 153 different targets. In addition, there are 2 suspended drugs and another 132 drugs where development has been ceased. Learn More